S&P 500   4,549.34
DOW   36,054.43
QQQ   385.05
14 best consumer staples dividend stocks
Lithium Discovery So BIG You Can't Miss it, Even From Space (Ad)
How to find blue-chip dividend stocks
Ex dividend date vs record date: What’s the difference?
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
What is the consumer staples sector?
6 best online and direct marketing retail stocks to invest in
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Last chance to set up your portfolio for OPEC cuts
What does consumer price index measure?
S&P 500   4,549.34
DOW   36,054.43
QQQ   385.05
14 best consumer staples dividend stocks
Lithium Discovery So BIG You Can't Miss it, Even From Space (Ad)
How to find blue-chip dividend stocks
Ex dividend date vs record date: What’s the difference?
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
What is the consumer staples sector?
6 best online and direct marketing retail stocks to invest in
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Last chance to set up your portfolio for OPEC cuts
What does consumer price index measure?
S&P 500   4,549.34
DOW   36,054.43
QQQ   385.05
14 best consumer staples dividend stocks
Lithium Discovery So BIG You Can't Miss it, Even From Space (Ad)
How to find blue-chip dividend stocks
Ex dividend date vs record date: What’s the difference?
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
What is the consumer staples sector?
6 best online and direct marketing retail stocks to invest in
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Last chance to set up your portfolio for OPEC cuts
What does consumer price index measure?
S&P 500   4,549.34
DOW   36,054.43
QQQ   385.05
14 best consumer staples dividend stocks
Lithium Discovery So BIG You Can't Miss it, Even From Space (Ad)
How to find blue-chip dividend stocks
Ex dividend date vs record date: What’s the difference?
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
What is the consumer staples sector?
6 best online and direct marketing retail stocks to invest in
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Last chance to set up your portfolio for OPEC cuts
What does consumer price index measure?

Reata Pharmaceuticals (RETA) Stock Forecast & Price Target

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$172.32
▼
$172.46
50-Day Range
$168.70
▼
$172.36
52-Week Range
$21.83
▼
$172.46
Volume
1.99 million shs
Average Volume
1.09 million shs
Market Capitalization
$6.58 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$157.90
Stock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaSustainability

Reata Pharmaceuticals Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Hold
Based on 13 Analyst Ratings

Analysts' Consensus Price Target

$157.90
-8.39% Downside
High Forecast$173.00
Average Forecast$157.90
Low Forecast$115.00
TypeCurrent Forecast
12/7/22 to 12/7/23		1 Month Ago
11/7/22 to 11/7/23		3 Months Ago
9/8/22 to 9/8/23		1 Year Ago
12/7/21 to 12/7/22
Consensus Rating
Hold
Hold
Hold
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
4 Buy rating(s)
4 Buy rating(s)
4 Buy rating(s)
4 Buy rating(s)
Hold
9 Hold rating(s)
9 Hold rating(s)
9 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$157.90$157.90$150.36$62.14
Predicted Upside-8.39% Downside9.68% Upside8.49% Upside59.91% Upside
Get Reata Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for RETA and its competitors with MarketBeat's FREE daily newsletter.


RETA Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

RETA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Reata Pharmaceuticals Stock vs. The Competition

TypeReata PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.31
2.68
2.49
Consensus RatingHoldModerate BuyHold
Predicted Upside-8.39% Downside652.27% Upside2,089.55% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/15/2023Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating		C. Duncan
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated RatingNeutral ➝ Neutral$172.00+1.78%
8/1/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeBuy ➝ Neutral$127.00 ➝ $172.50+4.18%
8/1/2023Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeOverweight ➝ Equal Weight$110.00 ➝ $172.00+3.88%
7/31/2023Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOutperform ➝ Outperform$85.00 ➝ $173.00+3.48%
7/31/2023LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeBuy ➝ Neutral$122.00 ➝ $172.50+3.18%
7/28/2023Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating		J. Schwartz
Subscribe to MarketBeat All Access for the recommendation accuracy rating		DowngradeOutperform ➝ Market Perform
7/28/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeOutperform ➝ Market Perform
7/28/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeBuy ➝ Hold$104.00 ➝ $172.50+3.18%
7/28/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeBuy ➝ Neutral
7/28/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeBuy ➝ Hold$110.00 ➝ $172.50+4.29%
7/6/2023TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageOutperform$140.00+34.74%
6/28/2023888
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingReiterates
6/12/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating		J. Schwartz
Subscribe to MarketBeat All Access for the recommendation accuracy rating		UpgradeMarket Perform ➝ Outperform
2/24/2023The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy$115.00 ➝ $117.00+135.18%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 05:50 AM ET.












RETA Price Target - Frequently Asked Questions

What is Reata Pharmaceuticals's consensus rating and price target?

According to the issued ratings of 13 analysts in the last year, the consensus rating for Reata Pharmaceuticals stock is Hold based on the current 9 hold ratings and 4 buy ratings for RETA. The average twelve-month price prediction for Reata Pharmaceuticals is $157.90 with a high price target of $173.00 and a low price target of $115.00. Learn more on RETA's analyst rating history.

Do Wall Street analysts like Reata Pharmaceuticals more than its competitors?

Analysts like Reata Pharmaceuticals less than other Medical companies. The consensus rating for Reata Pharmaceuticals is Hold while the average consensus rating for medical companies is Moderate Buy. Learn more on how RETA compares to other companies.

Does Reata Pharmaceuticals's stock price have much upside?

According to analysts, Reata Pharmaceuticals's stock has a predicted upside of 9.68% based on their 12-month stock forecasts.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NASDAQ:RETA) was last updated on 12/7/2023 by MarketBeat.com Staff

My Account -